BR112012018343A2 - "composições imunogênicas" - Google Patents

"composições imunogênicas"

Info

Publication number
BR112012018343A2
BR112012018343A2 BR112012018343A BR112012018343A BR112012018343A2 BR 112012018343 A2 BR112012018343 A2 BR 112012018343A2 BR 112012018343 A BR112012018343 A BR 112012018343A BR 112012018343 A BR112012018343 A BR 112012018343A BR 112012018343 A2 BR112012018343 A2 BR 112012018343A2
Authority
BR
Brazil
Prior art keywords
pneumoniae
immunogenic
immunogenic compositions
compositions
isolated
Prior art date
Application number
BR112012018343A
Other languages
English (en)
Portuguese (pt)
Inventor
Ljutic Belma
Ausar Fernando
Morefield Garry
Harper Kevin
Danielle Salha Marie
Ochs Ochs Martina
Gallichan Scott
Original Assignee
Sanofi Pasteur Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Ltd filed Critical Sanofi Pasteur Ltd
Publication of BR112012018343A2 publication Critical patent/BR112012018343A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1275—Streptococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR112012018343A 2009-12-22 2010-12-20 "composições imunogênicas" BR112012018343A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28923609P 2009-12-22 2009-12-22
US32566010P 2010-04-19 2010-04-19
PCT/CA2010/001977 WO2011075823A1 (en) 2009-12-22 2010-12-20 Immunogenic compositions

Publications (1)

Publication Number Publication Date
BR112012018343A2 true BR112012018343A2 (pt) 2017-06-27

Family

ID=44194860

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012018343A BR112012018343A2 (pt) 2009-12-22 2010-12-20 "composições imunogênicas"

Country Status (12)

Country Link
US (1) US20130183350A1 (cg-RX-API-DMAC10.html)
EP (1) EP2515938A4 (cg-RX-API-DMAC10.html)
JP (2) JP5894083B2 (cg-RX-API-DMAC10.html)
KR (1) KR20120107121A (cg-RX-API-DMAC10.html)
CN (1) CN102802664B (cg-RX-API-DMAC10.html)
AR (1) AR079712A1 (cg-RX-API-DMAC10.html)
AU (1) AU2010335970B2 (cg-RX-API-DMAC10.html)
BR (1) BR112012018343A2 (cg-RX-API-DMAC10.html)
CA (1) CA2783955A1 (cg-RX-API-DMAC10.html)
IL (2) IL220576B (cg-RX-API-DMAC10.html)
WO (1) WO2011075823A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201204628B (cg-RX-API-DMAC10.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011075822A1 (en) 2009-12-22 2011-06-30 Sanofi Pasteur Limited Immunogenic compositions and related methods
AU2011336366B2 (en) * 2010-12-03 2016-05-12 Sanofi Pasteur Limited Composition for immunization against Streptococcus pneumoniae
KR20140033127A (ko) 2011-05-17 2014-03-17 글락소스미스클라인 바이오로지칼즈 에스.에이. 스트렙토코쿠스 뉴모니애에 대한 백신
WO2014060385A1 (en) * 2012-10-17 2014-04-24 Glaxosmithkline Biologicals S.A. Immunogenic composition
GB201218660D0 (en) 2012-10-17 2012-11-28 Glaxosmithkline Biolog Sa Immunogenic composition
CA2894903A1 (en) * 2012-12-14 2014-06-19 Sanofi Pasteur, Ltd. Methods for assessing immunogenicity
CA2941826A1 (en) * 2014-03-10 2015-09-17 Sanofi Pasteur Limited Immunogenic compositions
KR101688960B1 (ko) * 2014-06-11 2016-12-23 전남대학교산학협력단 스쿠티카충 백신 조성물
CN107206066A (zh) * 2015-01-27 2017-09-26 3M创新有限公司 用于微针疫苗贴剂的含明矾的涂层制剂
US11173197B2 (en) 2015-07-07 2021-11-16 Bluewillow Biologics, Inc. Methods and compositions for nanoemulsion vaccine formulations
EP3736574A1 (en) * 2019-05-07 2020-11-11 Atlas Antibodies AB A formulation comprising an isotope labeled fusion polypeptide
WO2023034932A1 (en) * 2021-09-02 2023-03-09 Vaxcyte, Inc. Stabilization of adjuvanted vaccine compositions and their use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3237842B2 (ja) * 1988-12-16 2001-12-10 オランダ国 ニューモリシンミュータント及びそれから製造されたニューモコッカルワクチン
US6800744B1 (en) * 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
CA2355364C (en) * 1998-12-21 2014-03-18 Medimmune, Inc. Streptococcus pneumoniae proteins and immunogenic fragments for vaccines
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
GB0213622D0 (en) * 2002-06-13 2002-07-24 Glaxosmithkline Biolog Sa Vaccine Corporation
GB0410220D0 (en) * 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
DK1861120T3 (en) * 2005-03-23 2016-07-25 Glaxosmithkline Biologicals Sa Use of an influenza virus and an oil-in-water emulsion adjuvant to induce CD 4 T cell and / or enhanced B memory cell response
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
US20110002962A1 (en) 2006-08-17 2011-01-06 The Uab Research Foundation Immunogenic PcpA Polypeptides and Uses Thereof
CA2694466A1 (en) 2007-07-23 2009-01-29 Sanofi Pasteur Limited Immunogenic polypeptides and monoclonal antibodies
CN101952728B (zh) * 2008-02-01 2016-05-11 圣诺菲·帕斯图尔有限公司 用于诊断肺炎链球菌的试验
CN106008679A (zh) * 2008-12-24 2016-10-12 荷兰王国卫生福利和运动部国家公共卫生和环境研究所 修饰的肺炎链球菌溶血素(ply)多肽

Also Published As

Publication number Publication date
AU2010335970A1 (en) 2012-07-05
JP5894083B2 (ja) 2016-03-23
KR20120107121A (ko) 2012-09-28
ZA201204628B (en) 2013-02-27
EP2515938A4 (en) 2013-08-28
AR079712A1 (es) 2012-02-15
AU2010335970B2 (en) 2016-11-03
JP2013515015A (ja) 2013-05-02
IL242592A (en) 2017-10-31
CN102802664A (zh) 2012-11-28
IL220576B (en) 2018-03-29
JP2016104776A (ja) 2016-06-09
WO2011075823A1 (en) 2011-06-30
US20130183350A1 (en) 2013-07-18
CN102802664B (zh) 2017-04-05
EP2515938A1 (en) 2012-10-31
CA2783955A1 (en) 2011-06-30

Similar Documents

Publication Publication Date Title
GT201400097A (es) Agentes de iarn, composiciones y métodos de uso de los mismos para tratar enfermedades asociadas con transtiretina (ttr)
BR112014006822A2 (pt) proteínas de ligação ao antígeno cd27l
BRPI0922220A8 (pt) Uso de compostos antibacterianos, composição farmacêutica e combinação compreendendo os mesmos
BR112012012918A8 (pt) Agente indutor de apoptose para o tratamento de câncer e de doenças imunes e autoimunes
UY34701A (es) Formas sólidas de un profármaco de nucleótidos de tiofosforamidato
BR112015012933A2 (pt) proteínas de ligação ao antígeno bcma
GT201200172A (es) Derivados de sulfonamida como agentes inductores de apoptosis con selectividad por bcl-2 para el tratamiento de cáncer y enfermedades inmunes
GT201200258A (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
BR112017002221A2 (pt) 2-(morfolin-4-il)-1,7-naftiridinas
ECSP12011787A (es) Polipéptidos para unión al "receptor para productos finales de glicosilación avanzada" así como composiciones y métodos que implican a los mismos
CO6430436A2 (es) Inmunoconjugados dirigidos
BR112012009376A2 (pt) composição farmacêutica, forma de dosagem farmacêutica, processo para a sua preparação, métodos de tratamento e seu uso
HN2012000798A (es) Derivados de glicosidos y usos de los mismos.
EA201300987A1 (ru) Фармацевтические композиции, включающие метформин и ингибитор dpp-4 или ингибитор sglt-2
EA201001639A1 (ru) Композиции и способы их получения и применения
CU20100059A7 (es) Anticuerpos anti-esclerostina y proteínas funcionales
BR112012005713A2 (pt) vacinas direcionadas a célula langerhans.
BR112012021652A2 (pt) composto, uso do mesmo, e, composição farmacêutica
UY30572A1 (es) N-(1-ftalazin-1-il-piperidin-4-il)-amidas como moduladores del receptor ep2
BR112021025720A2 (pt) Conjugados anticorpo-fármaco de fator antitecido e métodos relacionados
UY30220A1 (es) Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo
BR112018014540A2 (pt) formulações/composições compreendendo inibidor de btk
BR112014025968A2 (pt) composição e processo para o recurtimento e engraxe de couro, e couro preparado
CO6321288A2 (es) Sales de compuestos inhibidores de vih
ECSP21003171A (es) Dinucleótidos cíclicos como agonistas de sting

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2545 DE 15-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.